Overview Request Sample Pages Request Customization Download PDF
You are viewing: Asia Pacific Cardiac Marker Testing Market analysis
Part of: Cardiac Marker Testing Market (Global)

The Asia Pacific Cardiac Marker Testing Market was valued at $750.1 Million in 2026 and projected to reach to $1364.4 Million by 2031, representing a compound annual growth rate of 12.7%. The Asia Pacific cardiac marker testing market is poised for exceptional growth through 2031, driven by demographic shifts toward aging populations and increased cardiovascular disease incidence across the region.

Asia Pacific Cardiac Marker Testing Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Cardiac Marker Testing Market Trends and Insights

  • Asia Pacific's growth trajectory reflects rising cardiovascular disease prevalence, aging populations, and increasing healthcare infrastructure investment across the region.
  • The market in Asia Pacific is driven by enhanced diagnostic capabilities, growing awareness of early cardiac detection, and expanding access to point-of-care testing solutions. Asia Pacific's cardiac marker testing sector benefits from rapid urbanization and lifestyle changes that elevate cardiac risk factors throughout the region.
  • Between 2026 and 2031, Asia Pacific is expected to capture significant market share as emerging economies strengthen their clinical laboratory networks and adopt advanced biomarker testing protocols.
  • Asia Pacific's competitive landscape includes both multinational diagnostics firms and regional players expanding their cardiac testing portfolios to meet growing demand..

Key Market Statistics

  • CAGR (2026-2031) 12.7% CAGR
  • Market Size, 2026 ~USD 750.1 Million
  • Forecast, 2031 ~USD 1364.4 Million
  • Geography Asia Pacific

Asia Pacific Cardiac Marker Testing Market Overview

Rapid Market Expansion :

Asia Pacific cardiac marker testing market is valued at USD 750.1 million in 2026 and projected to reach USD 1,364.4 million by 2031, representing a robust 12.7% CAGR, outpacing the global growth rate of 10.3%.

Rising Cardiovascular Disease Burden :

Escalating prevalence of cardiovascular diseases across Asia Pacific, driven by lifestyle changes, urbanization, and aging populations, is significantly increasing demand for early diagnostic cardiac marker testing solutions.

Healthcare Infrastructure Investment :

Substantial government and private sector investments in healthcare infrastructure across China, India, Japan, and Southeast Asia are enhancing diagnostic capabilities and accessibility of cardiac marker testing services.

China and Japan Market Leadership :

China dominates with USD 625.9 million market size, while Japan contributes USD 247.8 million, together representing over 85% of the Asia Pacific cardiac marker testing market value in 2026.

Asia Pacific Cardiac Marker Testing Market Dynamics

  • Enhanced diagnostic capabilities, coupled with rising healthcare expenditure and improved hospital infrastructure in emerging economies, are creating substantial opportunities for market expansion. Key growth catalysts include increasing awareness of early cardiac disease detection, adoption of advanced biomarker testing technologies, and regulatory support for diagnostic innovation.
  • China and Japan will continue leading market growth, while India and Southeast Asian nations present emerging opportunities.
  • Strategic partnerships between diagnostic companies and regional healthcare providers will accelerate market penetration and accessibility across Asia Pacific..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
    Top Companies

      Medical Devices

      Top Technologies
        Top Companies

          Key Takeaways

          • Asia Pacific's cardiac marker testing market will grow from USD 750.1M (2026) to USD 1,364.4M (2031), representing a 12.7% CAGR.
          • Asia Pacific's market expansion is fueled by rising cardiovascular disease incidence and aging demographics across the region.
          • Asia Pacific is witnessing increased adoption of point-of-care and high-sensitivity troponin testing in both urban and emerging healthcare settings.
          • Asia Pacific's competitive environment includes global diagnostics leaders and regional innovators strengthening their market presence through partnerships and product launches.

          Cardiac Marker Testing Market Report Scope

          Report Metric Details
          Base Year 2026
          Fastest Growing Segment OTHER CARDIAC BIOMARKERS (Biomarker Type)
          Forecast Period 2026–2031
          Growth Rate CAGR of 10.3% from 2026 to 2031
          Largest Segment SINGLEPLEX ASSAY (Assay Format)
          Market Size Base Year (Billions) ~USD 5.55 (2026)
          Revenue Forecast (Billions) ~USD 9.06 (2031)
          Segments Covered Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User

          Asia Pacific Cardiac Marker Testing Market Report Segmentation

          8 segment dimensions are covered across the global market.

          By Product

          • Instruments
          • Reagents & Kits

          By Technology

          • Clinical Chemistry
          • Immunoassay
          • Immunoassays

          By Type

          • Chemiluminescence
          • Contract Testing Laboratories
          • Elisa
          • Hospital Laboratories
          • Immunofluorescence
          • Lateral Flow Immunoassay
          • Reference Laboratories

          By Indication

          • Acute Coronary Syndrome
          • Atherosclerosis
          • Congestive Heart Failure
          • Ischemia
          • Myocardial Infarction

          By Biomarker Type

          • Brain Natriuretic Peptide
          • Creatinine Kinase-Mb
          • High-Sensitivity C-Reactive Protein
          • Homocysteine
          • Myoglobin
          • Other Cardiac Biomarkers
          • Troponin I & T

          By Point Of Testing

          • Lab Tests
          • Poc Tests

          By Assay Format

          • Multiplex Assay
          • Multiplex Assays
          • Singleplex Assay
          • Singleplex Assays

          By End User

          • Academic Institutes
          • Laboratory Testing Facilities
          • Point-Of-Care Testing

          Target Audience

          • Diagnostic Device Manufacturers : Cardiac marker testing equipment and reagent manufacturers need Asia Pacific market intelligence to identify growth opportunities, optimize product portfolios, and establish regional distribution networks.
          • Healthcare Providers & Hospitals : Hospital networks and diagnostic centers across Asia Pacific require market data to justify investments in cardiac testing infrastructure, benchmark performance, and plan service expansion.
          • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Asia Pacific need comprehensive market sizing and growth forecasts to assess investment returns and identify acquisition targets in cardiac diagnostics.
          • Pharmaceutical & Biotech Companies : Companies developing cardiac biomarkers and therapeutic solutions need Asia Pacific market insights to guide R&D investments, clinical trial planning, and commercialization strategies.
          • Healthcare Consultants & Advisors : Management consultants and healthcare advisors serving Asia Pacific clients require detailed market data to support strategic planning, competitive analysis, and business development initiatives.

          Key Companies in the Asia Pacific Cardiac Marker Testing Market

          CompanyHQOwnershipStrongest segments
          ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
          DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software),
          SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
          THERMO FISHER SCIENTIFICUnited StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
          BIO-RAD LABORATORIESUnited StatesPublic CompanyLife Science,Clinical Diagnostics,
          BIOMéRIEUX SAFrancePublic CompanyClinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA),
          BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
          DIASORIN SPAItalyPublic CompanyImmunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory,
          REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software,
          TOSOH CORPORATIONJapanPublic CompanyBasic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins),
          QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care,
          GUANGZHOU WONDFO BIOTECH CO., LTD.ChinaPublic CompanyRapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform,

          ABBOTT LABORATORIES

          Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.

          DANAHER CORPORATION

          Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.

          SIEMENS HEALTHINEERS AG

          Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.

          THERMO FISHER SCIENTIFIC

          Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

          BIO-RAD LABORATORIES

          Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.

          BIOMéRIEUX SA

          bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.

          BECTON, DICKINSON AND COMPANY

          Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.

          DIASORIN SPA

          DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.

          REVVITY

          Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

          TOSOH CORPORATION

          Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.

          QUIDEL CORPORATION

          Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.

          GUANGZHOU WONDFO BIOTECH CO., LTD.

          Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.

          Asia Pacific vs. other regions

          HowAsia Pacific compares to the other 3 regional blocs covered in this market.

          North America
          ~USD 2398.8 Million · 10.6% wtd CAGR ·
          Europe
          ~USD 1494.9 Million · 11.7% wtd CAGR ·
          Latin America
          ~USD 678.2 Million · 9.2% wtd CAGR ·
          Middle East & Africa
          ~USD 179.9 Million · 7.6% wtd CAGR ·

          Countries within Asia Pacific - compare and drill down

          Country2025 size (native)
          ChinaUSD 625.9 Million
          JapanUSD 247.8 Million
          IndiaUSD 213.3 Million
          South KoreaUSD 103.6 Million
          AustraliaUSD 76 Million
          Rest Of Asia PacificUSD 97.7 Million

          Country market size visualization

          China
          USD 625.9 Million
          Japan
          USD 247.8 Million
          India
          USD 213.3 Million
          South Korea
          USD 103.6 Million
          Australia
          USD 76 Million
          Rest Of Asia Pacific
          USD 97.7 Million

          Reasons to Buy this Report

          • Regional Market Sizing & Forecasts : Obtain precise market valuations for Asia Pacific cardiac marker testing with country-level breakdowns for China, Japan, India, Australia, and South Korea, enabling targeted investment and expansion strategies.
          • Growth Opportunity Identification : Identify high-growth segments and emerging markets within Asia Pacific experiencing accelerated cardiac disease prevalence and healthcare infrastructure development for strategic market entry.
          • Competitive Landscape Analysis : Understand regional competitive dynamics, key players, and market positioning specific to Asia Pacific to inform product development, partnerships, and go-to-market strategies.
          • Regulatory & Healthcare Insights : Access region-specific regulatory frameworks, reimbursement policies, and healthcare system structures across Asia Pacific countries to navigate market entry and operational challenges.
          • Demand Drivers & Trends : Leverage detailed analysis of Asia Pacific-specific demand drivers including aging demographics, disease prevalence trends, and technology adoption patterns to forecast revenue potential.

          Frequently asked questions

          What is the projected market size for cardiac marker testing in Asia Pacific by 2031?

          Asia Pacific's cardiac marker testing market is forecast to reach USD 1,364.4 million by 2031, growing from USD 750.1 million in 2026.

          What is the CAGR for Asia Pacific's cardiac marker testing market?

          Asia Pacific's cardiac marker testing market is expected to grow at a compound annual growth rate (CAGR) of 12.7% between 2026 and 2031.

          What factors are driving growth in Asia Pacific's cardiac marker testing market?

          Asia Pacific's market growth is driven by rising cardiovascular disease prevalence, aging populations, increased healthcare spending, expanding diagnostic infrastructure, and growing adoption of advanced biomarker testing technologies.

          Which cardiac markers are most commonly tested in Asia Pacific?

          Asia Pacific laboratories predominantly test high-sensitivity troponins, B-type natriuretic peptides (BNP), myoglobin, and creatine kinase-MB (CK-MB) for acute coronary syndrome and heart failure diagnosis.

          How is Asia Pacific's cardiac marker testing market segmented?

          Asia Pacific's market is segmented by test type (troponins, natriuretic peptides, myoglobin, others), technology platform (immunoassay, point-of-care, laboratory-based), end-user (hospitals, diagnostic centers, clinics), and country-level markets.

          RESEARCH METHODOLOGY

          The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.

          Secondary Research

          In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

          Primary Research

          In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

          BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS

          Cardiac Marker Testing Market Size, and Share

          Note 1: Others include sales managers, marketing managers, and product managers.
          Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

          COMPANY NAME

          DESIGNATION

          Abbott Laboratories (US)

          Sales Manager

          F. Hoffmann-La Roche AG (Switzerland)

          Product Manager

          To know about the assumptions considered for the study, download the pdf brochure

          Market Size Estimation

          Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:

          • The key players in the industry have been identified through extensive secondary research
          • The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
          • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

          The research methodology used to estimate the market size includes the following:

          Cardiac Marker Testing Market Top Down and Bottom Up Approach

          Data Triangulation

          After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

          Market Definition

          Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).

          Key Stakeholders

          • Product Manufacturers, Distributors, and Suppliers
          • Diagnostic Laboratories and Point-of-care Testing Centers
          • Research Laboratories and CROs
          • Ambulatory Testing Centers
          • Contract Testing Laboratories
          • Academic Universities and Medical Research Centers
          • Research & Development (R&D) Centers

          Report Objectives

          • To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
          • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
          • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
          • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
          • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
          • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
          • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
          • To study the impact of AI on the market, along with the macroeconomic outlook for each region

          Available customizations:

          MarketsandMarkets offers the following customizations for this market report.

          Country Information

          • Additional country-level analysis of the cardiac marker testing market

          Company profiles

          • Additional five company profiles of players operating in the cardiac marker testing market.

          Product Analysis

          • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market

           

          Get the Full Cardiac Marker Testing Market Report

          Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.

          Download Sample Pages Buy Report

          METHODOLOGY

          Need a Tailored Report?

          Customize this report to your needs

          Get 10% FREE Customization

          Customize This Report
          Fact checked
          Cite this Research
          DMCA.com Protection Status